Abdul Haseeb Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdul Haseeb Hasan has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Hassan
Department of Medicine, King Edward Medical University, Department of Medicine, Mayo Hospital, Lahore, Punjab, Pakistan
7 shared publicationsMohammad Azeem Malik
Lahore Punjab King Edward Medical University
5 shared publications- Minahil Rasul
Lahore Punjab The University of Lahore University College of Medicine and Dentistry
4 shared publications Muhammad Asad Jahangir
Department of Medicine, King Edward Medical University, Department of Medicine, Mayo Hospital, Lahore, Punjab, Pakistan
4 shared publicationsAffaf Mahmood
Medicine Lahore Punjab Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College
3 shared publications- Kawish Nenwani
Tando Adam Suleman Roshan Medical College
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1848
Efficacy and Safety of Rocatinlimab in Adults With Moderate‑to‑Severe Atopic Dermatitis: A Meta-analysis of Randomized Controlled Trials
Background Rocatinlimab, an anti-OX40 monoclonal antibody, is a novel therapy for moderate-to-severe atopic dermatitis (AD), a condition that significantly impairs quality of life. This meta-analysis evaluated its efficacy and safety. Methods Randomized controlled trials comparing rocatinlimab (150 mg and 300 mg) with placebo were included. Literature screening was performed using Zotero, and analyses were conducted with RevMan 5.4. Efficacy outcomes included EASI-75, EASI-90, vIGA-AD (0/1), pruritus NRS, and DLQI. Safety outcomes included treatment-emergent adverse events (TEAEs), serious adverse events, and specific side effects. Pooled odds ratios (ORs) with 95% CIs were calculated. Results Rocatinlimab significantly improved EASI-75 (OR 3.93), EASI-90 (OR 4.78), and vIGA-AD 0/1 (OR 3.33) at week 24. Pruritus and quality of life also improved. The 150 mg dose showed benefit for EASI-75 (OR 3.95) and pruritus (OR 2.98), though other outcomes were inconsistent. TEAEs were comparable to placebo. The 300 mg dose was associated with more mild adverse effects (e.g., headache, pyrexia, aphthous ulcers) but fewer severe events. Conclusion Rocatinlimab demonstrates dose-dependent efficacy with an acceptable safety profile, with 300 mg offering greater clinical benefit.
- 5 November 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1848
Open AccessEfficacy and Safety of Rocatinlimab in Adults With Moderate‑to‑Severe Atopic Dermatitis: A Meta-analysis of Randomized Controlled Trials
Background Rocatinlimab, an anti-OX40 monoclonal antibody, is a novel therapy for moderate-to-severe atopic dermatitis (AD), a condition that significantly impairs quality of life. This meta-analysis evaluated its efficacy and safety. Methods Randomized controlled trials comparing rocatinlimab (150 mg and 300 mg) with placebo were included. Literature screening was performed using Zotero, and analyses were conducted with RevMan 5.4. Efficacy outcomes included EASI-75, EASI-90, vIGA-AD (0/1), pruritus NRS, and DLQI. Safety outcomes included treatment-emergent adverse events (TEAEs), serious adverse events, and specific side effects. Pooled odds ratios (ORs) with 95% CIs were calculated. Results Rocatinlimab significantly improved EASI-75 (OR 3.93), EASI-90 (OR 4.78), and vIGA-AD 0/1 (OR 3.33) at week 24. Pruritus and quality of life also improved. The 150 mg dose showed benefit for EASI-75 (OR 3.95) and pruritus (OR 2.98), though other outcomes were inconsistent. TEAEs were comparable to placebo. The 300 mg dose was associated with more mild adverse effects (e.g., headache, pyrexia, aphthous ulcers) but fewer severe events. Conclusion Rocatinlimab demonstrates dose-dependent efficacy with an acceptable safety profile, with 300 mg offering greater clinical benefit.
- 28 October 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.
- 28 October 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88  (11) , 7399-7412
Comparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88  (11) , 7399-7412
Open AccessComparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- Open Access
- 12 September 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1532
Anesthetic Approaches for Left Atrial Appendage Occlusion: Comparing Conscious Sedation and General Anesthesia: A Meta Analysis
Background Left atrial appendage occlusion (LAAO) offers a mechanical alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation patients. However, the optimal anesthetic strategy—general anesthesia (GA) versus conscious sedation (CS)—during LAAO remains unclear. Methods A systematic search of PubMed, Google Scholar, Cochrane, and ScienceDirect was conducted up to September 2024. Studies comparing CS and GA during LAAO were included. Statistical analyses were performed using RevMan 5.4, reporting pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs). Results Three studies involving 1,395 patients were included. Conscious sedation was associated with a significantly lower incidence of device-related thrombus (OR: 0.17 [0.03, 0.98], p = 0.05) and shorter procedure time (MD: −7.17 minutes [−9.34, −5.01], p < 0.0001). No significant differences were observed in pericardial tamponade ( p = 0.31), bleeding ( p = 0.27), shock ( p = 0.70), vascular hematoma ( p = 0.95), stroke ( p = 0.11), cardiovascular mortality ( p = 0.55), or all-cause mortality ( p = 0.85). Procedural outcomes, including technical success ( p = 0.36), procedural success ( p = 0.35), peri-device leak <5 mm ( p = 0.28), and fluoroscopy time ( p = 0.07), were also statistically similar between groups. Conclusion This meta-analysis suggests that conscious sedation during LAAO is associated with reduced device-related thrombus and shorter procedure duration without increasing complication or mortality risk. These findings support the use of conscious sedation as a safe and efficient anesthetic alternative in appropriately selected patients undergoing LAAO.
- 12 September 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1532
Open AccessAnesthetic Approaches for Left Atrial Appendage Occlusion: Comparing Conscious Sedation and General Anesthesia: A Meta Analysis
Background Left atrial appendage occlusion (LAAO) offers a mechanical alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation patients. However, the optimal anesthetic strategy—general anesthesia (GA) versus conscious sedation (CS)—during LAAO remains unclear. Methods A systematic search of PubMed, Google Scholar, Cochrane, and ScienceDirect was conducted up to September 2024. Studies comparing CS and GA during LAAO were included. Statistical analyses were performed using RevMan 5.4, reporting pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs). Results Three studies involving 1,395 patients were included. Conscious sedation was associated with a significantly lower incidence of device-related thrombus (OR: 0.17 [0.03, 0.98], p = 0.05) and shorter procedure time (MD: −7.17 minutes [−9.34, −5.01], p < 0.0001). No significant differences were observed in pericardial tamponade ( p = 0.31), bleeding ( p = 0.27), shock ( p = 0.70), vascular hematoma ( p = 0.95), stroke ( p = 0.11), cardiovascular mortality ( p = 0.55), or all-cause mortality ( p = 0.85). Procedural outcomes, including technical success ( p = 0.36), procedural success ( p = 0.35), peri-device leak <5 mm ( p = 0.28), and fluoroscopy time ( p = 0.07), were also statistically similar between groups. Conclusion This meta-analysis suggests that conscious sedation during LAAO is associated with reduced device-related thrombus and shorter procedure duration without increasing complication or mortality risk. These findings support the use of conscious sedation as a safe and efficient anesthetic alternative in appropriately selected patients undergoing LAAO.
- Open Access
- 8 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88  (10) , 6430-6440
Long-term mortality trends of COPD and respiratory failure among adults aged ≥25 years in the United States: an analysis of CDC WONDER data (1999–2023)
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States and frequently associated with advanced stages complicated by respiratory failure (RF), a major terminal event that has been epidemiologically associated with significantly higher mortality risk among COPD patients. Despite this, long-term population-level trends in COPD-related mortality complicated by RF remain insufficiently characterized. We aimed to quantify long-term mortality trends of COPD and RF among adults aged 25 years or older in the United States from 1999 to 2023 by analyzing age-adjusted mortality rates (AAMRs), annual percent changes (APCs), and demographic and geographic variations using the CDC Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Using national multiple-cause-of-death data from 1999 to 2023, we identified deaths in which COPD and respiratory failure were co-listed using ICD-10 codes. Mortality trends were assessed using Joinpoint regression analysis to estimate APC, along with 95% confidence intervals (CIs) and statistical significance testing ( P < 0.05). AAMRs were calculated per 100 000 population using the direct standardization method based on the 2000 U.S. standard population. CDC WONDER is a publicly available, population-based mortality database maintained by the Centers for Disease Control and Prevention, which provides de-identified national death certificate data. A total of 1 393 458 adults aged 25 years or older died from COPD and RF between 1999 and 2023. The overall AAMR was 24.9 per 100 000 (95% CI: 24.8–24.9) with a significant increasing trend (APC: 0.88%, 95% CI: 0.41–1.38, P < 0.0008). Men had higher mortality than women (29.1 vs 22.1 per 100 000), while women showed a faster increase (APC: 1.27% vs 0.29%). White adults had the highest mortality rate (26.3 per 100 000), while Asian or Pacific Islanders had the lowest (8.7 per 100 000). The Midwest showed the steepest rising trend (APC: 2.25%, P < 0.000001), while other regions showed lower or non-significant changes. West Virginia had the highest state-level mortality, and Hawaii the lowest. Targeted public health strategies focusing on smoking cessation, early screening of high-risk populations, improved access to pulmonary care, and reduction of regional healthcare disparities may help address factors associated with COPD- and respiratory failure–related mortality in the United States. These findings represent population-level associations and should not be interpreted as causal relationships.
- 8 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88  (10) , 6430-6440
Open AccessLong-term mortality trends of COPD and respiratory failure among adults aged ≥25 years in the United States: an analysis of CDC WONDER data (1999–2023)
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States and frequently associated with advanced stages complicated by respiratory failure (RF), a major terminal event that has been epidemiologically associated with significantly higher mortality risk among COPD patients. Despite this, long-term population-level trends in COPD-related mortality complicated by RF remain insufficiently characterized. We aimed to quantify long-term mortality trends of COPD and RF among adults aged 25 years or older in the United States from 1999 to 2023 by analyzing age-adjusted mortality rates (AAMRs), annual percent changes (APCs), and demographic and geographic variations using the CDC Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Using national multiple-cause-of-death data from 1999 to 2023, we identified deaths in which COPD and respiratory failure were co-listed using ICD-10 codes. Mortality trends were assessed using Joinpoint regression analysis to estimate APC, along with 95% confidence intervals (CIs) and statistical significance testing ( P < 0.05). AAMRs were calculated per 100 000 population using the direct standardization method based on the 2000 U.S. standard population. CDC WONDER is a publicly available, population-based mortality database maintained by the Centers for Disease Control and Prevention, which provides de-identified national death certificate data. A total of 1 393 458 adults aged 25 years or older died from COPD and RF between 1999 and 2023. The overall AAMR was 24.9 per 100 000 (95% CI: 24.8–24.9) with a significant increasing trend (APC: 0.88%, 95% CI: 0.41–1.38, P < 0.0008). Men had higher mortality than women (29.1 vs 22.1 per 100 000), while women showed a faster increase (APC: 1.27% vs 0.29%). White adults had the highest mortality rate (26.3 per 100 000), while Asian or Pacific Islanders had the lowest (8.7 per 100 000). The Midwest showed the steepest rising trend (APC: 2.25%, P < 0.000001), while other regions showed lower or non-significant changes. West Virginia had the highest state-level mortality, and Hawaii the lowest. Targeted public health strategies focusing on smoking cessation, early screening of high-risk populations, improved access to pulmonary care, and reduction of regional healthcare disparities may help address factors associated with COPD- and respiratory failure–related mortality in the United States. These findings represent population-level associations and should not be interpreted as causal relationships.
- Open Access
- 31 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1460
Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may provide greater efficacy. This systematic review and meta-analysis compared the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM. Methods PubMed, Embase, Cochrane Library, and ScienceDirect were searched through May 2026 for randomized controlled trials comparing mazdutide with dulaglutide. Outcomes included glycemic control, weight loss, cardiometabolic parameters, and safety. Data were pooled using fixed- or random-effects models according to heterogeneity, and certainty of evidence was assessed using the GRADE framework. Results Three RCTs involving 990 participants (mazdutide, n=683; dulaglutide, n=307) were included. Mazdutide significantly reduced HbA1c (mean difference [MD] −0.25%; 95% CI −0.38 to −0.12; p=0.0002) and body weight (MD −3.74%; 95% CI −5.29 to −2.19; p<0.00001) compared with dulaglutide. It also increased the likelihood of achieving ≥5% and ≥10% weight loss and improved blood pressure and triglyceride levels. No significant differences were observed in fasting plasma glucose or HbA1c target achievement (<7%). Treatment-emergent adverse events were more frequent with mazdutide (OR 1.69; 95% CI 1.16–2.45), mainly due to gastrointestinal effects, while serious adverse events were similar between groups. GRADE certainty was high for primary efficacy outcomes, moderate for most safety outcomes, and low to very low for infrequent adverse events. Conclusions Mazdutide demonstrated superior glycemic control, weight reduction, and cardiometabolic benefits compared with dulaglutide, with more frequent but generally mild gastrointestinal adverse events. These findings support mazdutide as a promising treatment option for T2DM, although longer-term comparative studies are needed.
- 31 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1460
Open AccessComparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may provide greater efficacy. This systematic review and meta-analysis compared the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM. Methods PubMed, Embase, Cochrane Library, and ScienceDirect were searched through May 2026 for randomized controlled trials comparing mazdutide with dulaglutide. Outcomes included glycemic control, weight loss, cardiometabolic parameters, and safety. Data were pooled using fixed- or random-effects models according to heterogeneity, and certainty of evidence was assessed using the GRADE framework. Results Three RCTs involving 990 participants (mazdutide, n=683; dulaglutide, n=307) were included. Mazdutide significantly reduced HbA1c (mean difference [MD] −0.25%; 95% CI −0.38 to −0.12; p=0.0002) and body weight (MD −3.74%; 95% CI −5.29 to −2.19; p<0.00001) compared with dulaglutide. It also increased the likelihood of achieving ≥5% and ≥10% weight loss and improved blood pressure and triglyceride levels. No significant differences were observed in fasting plasma glucose or HbA1c target achievement (<7%). Treatment-emergent adverse events were more frequent with mazdutide (OR 1.69; 95% CI 1.16–2.45), mainly due to gastrointestinal effects, while serious adverse events were similar between groups. GRADE certainty was high for primary efficacy outcomes, moderate for most safety outcomes, and low to very low for infrequent adverse events. Conclusions Mazdutide demonstrated superior glycemic control, weight reduction, and cardiometabolic benefits compared with dulaglutide, with more frequent but generally mild gastrointestinal adverse events. These findings support mazdutide as a promising treatment option for T2DM, although longer-term comparative studies are needed.
- Open Access
- 25 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1423
Efficacy and Safety of Avacopan in patients with ANCA-associated vasculitis: A Systematic Review and Meta-analysis
Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune vasculitis characterized by inflammation of small- to medium-sized blood vessels. While conventional treatments such as glucocorticoids and immunosuppressant improve disease control, they carry a high burden of toxicity. Avacopan, an oral complement 5a receptor inhibitor, has emerged as a potential steroid-sparing therapy. This meta-analysis aimed to evaluate the efficacy and safety of avacopan in patients with AAV. Methods This systematic review and meta-analysis followed PRISMA guidelines. A total of seven randomized controlled trials involving patients with AAV were included. Primary outcomes assessed included clinical efficacy (remission at 26 and 52 weeks, relapse, and vasculitis worsening), glucocorticoid toxicity, safety and tolerability, and organ-specific adverse effects. Pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Results Avacopan demonstrated significantly higher remission rates at 52 weeks (OR 1.79; 95% CI: 1.18–2.72; p = 0.006) and lower relapse rates (OR 0.39; 95% CI: 0.21–0.72; p = 0.003) compared to standard care. Steroid-related toxicity was significantly reduced, with lower GTI-AIS and cumulative worsening scores at 13 and 26 weeks. Notably, avacopan reduced infection rates (OR 0.69; p = 0.02) and adverse psychiatric events (OR 0.55; p = 0.03). While other adverse events were numerically lower, they were not statistically significant, indicating a comparable or improved safety profile. Conclusion Avacopan improves long-term clinical outcomes and reduces glucocorticoid-related toxicity in AAV, representing a safer, effective adjunct to standard therapy.
- 25 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1423
Open AccessEfficacy and Safety of Avacopan in patients with ANCA-associated vasculitis: A Systematic Review and Meta-analysis
Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune vasculitis characterized by inflammation of small- to medium-sized blood vessels. While conventional treatments such as glucocorticoids and immunosuppressant improve disease control, they carry a high burden of toxicity. Avacopan, an oral complement 5a receptor inhibitor, has emerged as a potential steroid-sparing therapy. This meta-analysis aimed to evaluate the efficacy and safety of avacopan in patients with AAV. Methods This systematic review and meta-analysis followed PRISMA guidelines. A total of seven randomized controlled trials involving patients with AAV were included. Primary outcomes assessed included clinical efficacy (remission at 26 and 52 weeks, relapse, and vasculitis worsening), glucocorticoid toxicity, safety and tolerability, and organ-specific adverse effects. Pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Results Avacopan demonstrated significantly higher remission rates at 52 weeks (OR 1.79; 95% CI: 1.18–2.72; p = 0.006) and lower relapse rates (OR 0.39; 95% CI: 0.21–0.72; p = 0.003) compared to standard care. Steroid-related toxicity was significantly reduced, with lower GTI-AIS and cumulative worsening scores at 13 and 26 weeks. Notably, avacopan reduced infection rates (OR 0.69; p = 0.02) and adverse psychiatric events (OR 0.55; p = 0.03). While other adverse events were numerically lower, they were not statistically significant, indicating a comparable or improved safety profile. Conclusion Avacopan improves long-term clinical outcomes and reduces glucocorticoid-related toxicity in AAV, representing a safer, effective adjunct to standard therapy.
- Open Access
- 20 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1398
Comparative Efficacy and Safety of Pulsed Field Ablation and Conventional Thermal Ablation for Atrial Fibrillation: A GRADE assessed Systematic Review and Meta analysis of Randomized Controlled Trials
Background Pulsed field ablation (PFA) is a nonthermal alternative to conventional thermal ablation (TA) for atrial fibrillation (AF), but comparative certainty across outcomes remains variable. Methods We systematically reviewed randomized controlled trials comparing PFA with radiofrequency or cryoballoon ablation. Primary analyses were restricted to paroxysmal AF; exploratory analyses incorporated trials enrolling persistent or mixed AF populations. Random-effects meta-analyses evaluated efficacy, safety, quality of life, and procedural outcomes, with certainty assessed using GRADE. Results Four RCTs (1,393 participants) contributed to the primary analyses. PFA did not differ from TA in atrial arrhythmia recurrence (RR 1.00, 95% CI 0.67–1.49) or single-procedure success (RR 1.04, 95% CI 0.92–1.17). Serious adverse events were also similar (RR 0.94, 95% CI 0.71–1.25). PFA significantly reduced skin-to-skin procedural time (MD −17.04 minutes, 95% CI −20.84 to −13.23). Exploratory analyses incorporating two additional RCTs generally supported these findings, including similar recurrence (RR 0.95, 95% CI 0.78–1.16) and single-procedure success (RR 1.06, 95% CI 0.99–1.13). Certainty ranged from moderate to very low across outcomes, with risk of bias, imprecision, and inconsistency contributing to downgrading. Conclusion PFA provides similar rhythm efficacy and overall safety to contemporary TA while reducing selected procedural times. However, confidence in individual estimates varies, particularly for rare complications and exploratory procedural outcomes. Further randomized evidence with longer follow-up is needed.
- 20 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1398
Open AccessComparative Efficacy and Safety of Pulsed Field Ablation and Conventional Thermal Ablation for Atrial Fibrillation: A GRADE assessed Systematic Review and Meta analysis of Randomized Controlled Trials
Background Pulsed field ablation (PFA) is a nonthermal alternative to conventional thermal ablation (TA) for atrial fibrillation (AF), but comparative certainty across outcomes remains variable. Methods We systematically reviewed randomized controlled trials comparing PFA with radiofrequency or cryoballoon ablation. Primary analyses were restricted to paroxysmal AF; exploratory analyses incorporated trials enrolling persistent or mixed AF populations. Random-effects meta-analyses evaluated efficacy, safety, quality of life, and procedural outcomes, with certainty assessed using GRADE. Results Four RCTs (1,393 participants) contributed to the primary analyses. PFA did not differ from TA in atrial arrhythmia recurrence (RR 1.00, 95% CI 0.67–1.49) or single-procedure success (RR 1.04, 95% CI 0.92–1.17). Serious adverse events were also similar (RR 0.94, 95% CI 0.71–1.25). PFA significantly reduced skin-to-skin procedural time (MD −17.04 minutes, 95% CI −20.84 to −13.23). Exploratory analyses incorporating two additional RCTs generally supported these findings, including similar recurrence (RR 0.95, 95% CI 0.78–1.16) and single-procedure success (RR 1.06, 95% CI 0.99–1.13). Certainty ranged from moderate to very low across outcomes, with risk of bias, imprecision, and inconsistency contributing to downgrading. Conclusion PFA provides similar rhythm efficacy and overall safety to contemporary TA while reducing selected procedural times. However, confidence in individual estimates varies, particularly for rare complications and exploratory procedural outcomes. Further randomized evidence with longer follow-up is needed.
- Open Access
- 17 August 2026
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 16
Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies
Background: Individuals with schizophrenia spectrum disorders are at increased risk of cardiometabolic complications, largely due to antipsychotic-associated metabolic effects. Effective management strategies remain limited. Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown metabolic benefits in the general population, but its role in this population remains unclear. Objective: To evaluate the efficacy and safety of semaglutide compared with placebo in individuals with schizophrenia spectrum disorders receiving antipsychotic therapy and experiencing metabolic abnormalities. Design: Systematic review and meta-analysis of randomized controlled trials. Data Sources: and Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Cochrane Library, Embase, and ScienceDirect were searched from inception to February 2026. Randomized controlled trials comparing semaglutide with placebo were included. The longest follow-up time point from each study was used for pooled analysis. Mean differences (MD) and odds ratios (OR) with 95% confidence intervals (CIs) were calculated using RevMan 5.4. The certainty of evidence for critical outcomes was assessed using the GRADE framework. Results: Three randomized controlled trials (n = 258) were included. Semaglutide was associated with reductions in body weight (MD: -11.01 kg), BMI (MD: -3.63 kg/m 2 ), and waist circumference (MD: -6.33 cm). Improvements were also observed in body composition. No significant differences were found in lipid or glycemic parameters except HbA1c which showed a significant reduction. Psychiatric outcomes remained unchanged. Gastrointestinal adverse particularly nausea and vomiting events were more frequent with semaglutide. Conclusion: Semaglutide appears to improve anthropometric outcomes without worsening psychiatric symptoms in individuals receiving antipsychotic therapy. However, evidence is limited, and larger, long-term trials are required. According to the GRADE framework, the certainty of evidence ranged from moderate for key anthropometric and safety outcomes to low or very low for several metabolic and psychiatric outcomes, highlighting the need for larger, long-term randomized trials.
- 17 August 2026
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 16
Open AccessEfficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies
Background: Individuals with schizophrenia spectrum disorders are at increased risk of cardiometabolic complications, largely due to antipsychotic-associated metabolic effects. Effective management strategies remain limited. Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown metabolic benefits in the general population, but its role in this population remains unclear. Objective: To evaluate the efficacy and safety of semaglutide compared with placebo in individuals with schizophrenia spectrum disorders receiving antipsychotic therapy and experiencing metabolic abnormalities. Design: Systematic review and meta-analysis of randomized controlled trials. Data Sources: and Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Cochrane Library, Embase, and ScienceDirect were searched from inception to February 2026. Randomized controlled trials comparing semaglutide with placebo were included. The longest follow-up time point from each study was used for pooled analysis. Mean differences (MD) and odds ratios (OR) with 95% confidence intervals (CIs) were calculated using RevMan 5.4. The certainty of evidence for critical outcomes was assessed using the GRADE framework. Results: Three randomized controlled trials (n = 258) were included. Semaglutide was associated with reductions in body weight (MD: -11.01 kg), BMI (MD: -3.63 kg/m 2 ), and waist circumference (MD: -6.33 cm). Improvements were also observed in body composition. No significant differences were found in lipid or glycemic parameters except HbA1c which showed a significant reduction. Psychiatric outcomes remained unchanged. Gastrointestinal adverse particularly nausea and vomiting events were more frequent with semaglutide. Conclusion: Semaglutide appears to improve anthropometric outcomes without worsening psychiatric symptoms in individuals receiving antipsychotic therapy. However, evidence is limited, and larger, long-term trials are required. According to the GRADE framework, the certainty of evidence ranged from moderate for key anthropometric and safety outcomes to low or very low for several metabolic and psychiatric outcomes, highlighting the need for larger, long-term randomized trials.